See more : Xinming China Holdings Limited (2699.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Perspective Therapeutics, Inc. (CATX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Perspective Therapeutics, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Pharming Group N.V. (PHARM.AS) Income Statement Analysis – Financial Results
- First Philippine Holdings Corporation (FPHHF) Income Statement Analysis – Financial Results
- Prime Mining Corp. (O4V3.F) Income Statement Analysis – Financial Results
- Willis Towers Watson Public Limited Company (0Y4Q.L) Income Statement Analysis – Financial Results
- Nemaska Lithium Inc. (NMX.TO) Income Statement Analysis – Financial Results
Perspective Therapeutics, Inc. (CATX)
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.43M | 7.10M | 10.80M | 10.05M | 9.68M | 7.31M | 5.92M | 4.76M | 4.77M | 4.61M | 4.22M | 4.53M | 5.07M | 5.24M | 5.29M | 5.42M | 7.16M | 5.74M | 1.99M | 201.73K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.85M | 8.26M | 7.82M | 6.79M |
| Cost of Revenue | 0.00 | 5.47M | 6.18M | 4.93M | 4.56M | 4.27M | 4.08M | 3.92M | 4.64M | 4.44M | 4.42M | 4.38M | 4.37M | 4.08M | 4.56M | 5.77M | 7.31M | 5.79M | 3.82M | 1.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.68M | 7.46M | 6.99M | 6.42M |
| Gross Profit | 1.43M | 1.63M | 4.62M | 5.12M | 5.12M | 3.05M | 1.84M | 838.00K | 129.15K | 167.39K | -196.47K | 150.18K | 703.20K | 1.16M | 725.80K | -353.33K | -151.43K | -54.60K | -1.82M | -1.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.16M | 795.61K | 822.28K | 367.89K |
| Gross Profit Ratio | 100.00% | 23.00% | 42.76% | 50.94% | 52.93% | 41.66% | 31.10% | 17.60% | 2.71% | 3.63% | -4.66% | 3.32% | 13.87% | 22.09% | 13.73% | -6.52% | -2.12% | -0.95% | -91.30% | -630.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 14.84% | 9.63% | 10.52% | 5.42% |
| Research & Development | 21.31M | 2.60M | 2.58M | 1.43M | 1.13M | 1.47M | 1.75M | 965.00K | 528.05K | 614.77K | 668.80K | 627.11K | 730.58K | 465.33K | 340.96K | 958.67K | 1.36M | 1.35M | 450.43K | 137.53K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 20.97M | 10.87M | 6.62M | 4.69M | 4.57M | 4.17M | 4.17M | 3.92M | 3.79M | 2.40M | 2.49M | 2.29M | 2.36M | 2.42M | 2.44M | 2.79M | 7.29M | 8.30M | 4.92M | 0.00 | 30.00K | 9.10K | 19.02K | 7.58K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 97.00K | 3.23M | 2.80M | 2.44M | 2.98M | 2.68M | 2.66M | 2.31M | 1.35M | 1.49M | 1.23M | 1.30M | 1.22M | 1.23M | 1.95M | 2.37M | 0.00 | 0.00 | 0.00 | 0.00 | -20.91K | 9.93K | -11.44K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 21.06M | 14.21M | 9.43M | 7.13M | 7.55M | 6.85M | 6.83M | 6.23M | 5.14M | 3.89M | 3.72M | 3.59M | 3.57M | 3.66M | 4.39M | 5.16M | 7.29M | 8.30M | 4.92M | 2.57M | 9.10K | 19.02K | 7.58K | 7.58K | 0.00 | 15.53K | 221.88K | 1.11M | 2.59M | 1.24M | 1.23M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | -73.00K | 2.00K | 0.00 | -48.00K | -456.28K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.99K | 15.57K | 0.00 | 207.30K | 942.00 | 317.97K | 316.74K | 406.92K |
| Operating Expenses | 42.38M | 17.43M | 12.01M | 8.56M | 8.60M | 8.33M | 8.57M | 7.15M | 5.21M | 4.50M | 4.39M | 4.22M | 4.30M | 4.12M | 4.73M | 6.12M | 8.65M | 9.65M | 5.37M | 2.71M | 9.10K | 19.02K | 7.58K | 15.57K | 14.15K | 15.53K | 222.83K | 1.43M | 2.91M | 1.65M | 1.54M |
| Cost & Expenses | 42.38M | 22.90M | 18.19M | 13.49M | 13.16M | 12.59M | 12.65M | 11.07M | 9.85M | 8.94M | 8.81M | 8.59M | 8.67M | 8.20M | 9.29M | 11.89M | 15.96M | 15.44M | 9.19M | -4.18M | 9.10K | 19.02K | 7.58K | 15.57K | 14.15K | 15.53K | 222.83K | 8.11M | 10.37M | 8.64M | 7.96M |
| Interest Income | 934.00K | 1.12M | 119.00K | 59.00K | 30.00K | 108.00K | 29.00K | 118.00K | 218.15K | 282.75K | 12.11K | 664.00 | 747.00 | 3.38K | 11.43K | 111.05K | 0.00 | 0.00 | 0.00 | 2.39K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 84.00K | 0.00 | 119.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 950.00 | 2.21K | 883.00 | 7.00 | 61.68K | 216.61K | 36.39K | 75.31K | 274.00K | 0.00 | 1.02M | 167.49K | 0.00 | 2.10K | 41.01K | 51.50K | 0.00 | 0.00 | -12.44K | 0.00 | 163.27K | 66.96K | 108.63K |
| Depreciation & Amortization | 981.00K | 344.00K | 248.00K | 9.00K | 147.00K | -24.00K | 80.00K | 68.00K | 470.85K | 576.38K | 685.40K | 739.15K | 847.12K | 888.57K | 996.88K | 1.21M | 1.06M | 715.25K | 655.33K | 143.04K | 0.00 | 84.85K | -41.01K | -51.50K | 250.68K | -51.50K | 942.00 | 317.97K | 316.74K | 407.42K | 308.83K |
| EBITDA | -39.96M | -14.84M | -7.39M | -3.43M | -3.48M | -5.30M | -6.70M | -6.19M | -4.39M | -4.05M | -3.89M | -3.33M | -2.92M | -2.07M | -3.01M | -5.54M | -7.47M | -8.98M | -6.15M | -3.96M | -9.10K | -19.02K | -7.58K | -15.57K | -14.15K | -15.53K | -234.32K | 13.87K | -2.69M | -436.43K | -1.78M |
| EBITDA Ratio | -2,786.61% | -208.87% | -68.47% | -34.10% | -35.91% | -72.49% | -113.12% | -129.99% | -92.11% | -87.99% | -92.22% | -73.53% | -57.60% | -39.53% | -56.98% | -102.21% | -104.32% | -156.58% | -308.60% | -1,962.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.18% | -32.56% | -5.58% | -26.22% |
| Operating Income | -40.94M | -15.18M | -7.39M | -3.44M | -3.48M | -5.28M | -6.73M | -6.31M | -5.08M | -4.34M | -4.59M | -4.07M | -3.60M | -2.96M | -4.01M | -6.47M | -8.80M | -9.70M | -7.20M | -3.98M | -9.10K | -19.02K | -7.58K | -15.57K | -14.15K | -15.53K | -222.83K | -260.71K | -2.11M | -827.94K | -1.17M |
| Operating Income Ratio | -2,855.02% | -213.71% | -68.47% | -34.19% | -35.91% | -72.16% | -113.61% | -132.47% | -106.56% | -94.13% | -108.75% | -89.88% | -70.95% | -56.56% | -75.84% | -119.43% | -122.97% | -169.04% | -360.79% | -1,974.51% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -3.32% | -25.55% | -10.59% | -17.21% |
| Total Other Income/Expenses | 835.00K | 512.00K | 119.00K | 50.00K | 30.00K | 134.00K | 29.00K | 27.00K | 154.00K | 374.61K | -1.38M | 210.00K | 170.00K | 334.00K | 0.00 | 274.00K | -274.00K | 0.00 | -385.51K | -285.99K | -2.10K | -2.10K | -41.01K | -51.50K | 0.00 | 0.00 | 12.44K | 43.40K | 895.74K | 15.91K | 920.60K |
| Income Before Tax | -40.11M | -14.67M | -7.27M | -3.39M | -3.45M | -5.14M | -6.70M | -6.16M | -4.71M | -3.68M | -5.96M | -3.86M | -3.43M | -2.84M | 0.00 | -6.20M | -9.08M | 0.00 | -8.22M | -4.27M | -11.20K | -60.03K | -59.08K | -59.08K | 0.00 | 0.00 | -3.09K | -423.98K | -2.15M | -936.57K | -435.09K |
| Income Before Tax Ratio | -2,796.79% | -206.50% | -67.36% | -33.69% | -35.60% | -70.33% | -113.12% | -129.43% | -98.77% | -79.91% | -141.24% | -85.22% | -67.60% | -54.25% | 0.00% | -114.37% | -126.79% | 0.00% | -412.08% | -2,116.28% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5.40% | -26.03% | -11.98% | -6.41% |
| Income Tax Expense | -2.65M | 0.00 | -119.00K | -199.00K | -177.00K | -294.00K | -29.00K | -145.00K | -371.20K | -655.14K | 1.37M | -210.66K | -109.07K | -120.78K | 24.96K | -309.74K | -245.21K | -94.68K | 1.02M | 0.00 | -86.96K | -84.85K | 41.01K | 51.50K | -250.68K | 51.50K | -942.00 | 2.10K | 2.00K | 2.60K | 2.50K |
| Net Income | -46.51M | -14.67M | -7.15M | -3.19M | -3.27M | -4.85M | -6.70M | -6.16M | -4.71M | -3.68M | -5.96M | -3.86M | -3.49M | -2.84M | -4.03M | -6.16M | -8.56M | -9.61M | -8.22M | -4.27M | 75.76K | -60.03K | -59.08K | 235.11K | -65.65K | 1.82M | -139.55K | -426.08K | -2.15M | -939.17K | -437.59K |
| Net Income Ratio | -3,243.24% | -206.50% | -66.26% | -31.71% | -33.77% | -66.31% | -113.12% | -129.43% | -98.77% | -79.91% | -141.24% | -85.22% | -68.80% | -54.25% | -76.31% | -113.71% | -119.54% | -167.39% | -412.08% | -2,116.28% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5.43% | -26.06% | -12.01% | -6.45% |
| EPS | -1.40 | -0.10 | -0.05 | -0.03 | -0.05 | -0.07 | -0.12 | -0.11 | -0.09 | -0.07 | -0.14 | -0.11 | -0.12 | -0.11 | -0.18 | -0.27 | -0.37 | -0.54 | -0.68 | -197.24 | 0.03 | -0.07 | -0.18 | 0.60 | -0.20 | 5.41 | -0.42 | -1.29 | -6.63 | -3.27 | -1.52 |
| EPS Diluted | -1.40 | -0.10 | -0.05 | -0.03 | -0.05 | -0.07 | -0.12 | -0.11 | -0.09 | -0.07 | -0.14 | -0.11 | -0.12 | -0.11 | -0.18 | -0.27 | -0.37 | -0.54 | -0.68 | -197.24 | 0.03 | -0.07 | -0.18 | 0.60 | -0.20 | 5.41 | -0.42 | -1.29 | -6.63 | -3.27 | -1.52 |
| Weighted Avg Shares Out | 26.76M | 142.10M | 141.99M | 103.84M | 67.60M | 67.04M | 55.16M | 55.02M | 55.01M | 54.88M | 42.68M | 34.42M | 28.62M | 25.13M | 22.96M | 22.94M | 23.03M | 17.83M | 12.05M | 21.65K | 2.36M | 804.04K | 329.23K | 329.23K | 329.23K | 329.23K | 329.23K | 329.23K | 324.73K | 287.61K | 287.61K |
| Weighted Avg Shares Out (Dil) | 26.76M | 142.10M | 141.99M | 103.84M | 67.60M | 67.04M | 55.16M | 55.02M | 55.02M | 54.88M | 42.68M | 34.42M | 28.62M | 25.13M | 22.96M | 22.94M | 23.03M | 17.83M | 12.05M | 21.65K | 2.36M | 804.04K | 329.23K | 329.23K | 329.23K | 329.23K | 329.23K | 329.23K | 324.73K | 287.61K | 287.61K |
Perspective Commences Recruitment for Second Dose Escalation Cohorts in Clinical Studies of Two Lead Programs: [(212)Pb]VMT-α-NET and [(212)Pb]VMT01
SEATTLE, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), today announced that it began patient recruitment for the second dosing cohorts (Cohort 2) in clinical studies for both of its lead product candidates, [212Pb]VMT-α-NET and [212Pb]VMT01,...
Perspective Therapeutics Enters into Strategic Agreements with Lantheus Including Equity Investment, Co-Development Options, and Expansion of Manufacturing Capability
SEATTLE, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), today announced it entered into strategic agreements with Lantheus Holdings, Inc., the leading radiopharmaceutical-focused company, and its affiliates (Lantheus) (NASDAQ: LNTH). For an upfront payment of...
Perspective Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SEATTLE, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that Thijs Spoor, the Company's Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA,...
Perspective Therapeutics Announces First Patient Dosed in a Phase 1 Study of [(212)Pb]VMT-α-NET to Treat Refractory or Relapsed Neuroendocrine Tumors
SEATTLE, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), announced today that the first patient was dosed at the University of Iowa in an investigator-initiated Phase 1 trial evaluating the safety of [212Pb]VMT-α-NET,...
Perspective Therapeutics Reports Third Quarter Fiscal 2023 Results and Recent Business Highlights
SEATTLE, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), today announced third quarter financial results for the period ended September 30, 2023 and provided recent business highlights..
Perspective Therapeutics Completes Recruitment for First Patient Cohort in Phase 1/2a Dose Escalation Trial of VMT01 in Malignant Melanoma
SEATTLE, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced the completion of recruitment for the first patient cohort in its Phase 1/2a dose escalation study of 212Pb-VMT01 (clinicaltrials.gov identifier NCT05655312), its...
Perspective Therapeutics' Cesium-131 Featured at the American Society for Radiation Oncology's Annual Conference
SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy treatment options for multiple cancers, today...
Perspective Therapeutics to Present at the World Molecular Imaging Congress 2023
RICHLAND, WASH. & CORALVILLE, IOWA, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Perspective T h erapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that it will have two presentations at the upcoming World Molecular Imaging Congress (WMIC) 2023,...
Perspective Therapeutics (CATX) Reports Q2 Loss, Lags Revenue Estimates
Perspective Therapeutics (CATX) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.01 per share a year ago.
Perspective Therapeutics Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of VMT01 of its Targeted Alpha-Particle Therapy (TAT), for Treatment of MC1R-positive Metastatic Melanoma
RICHLAND, Wash. & CORALVILLE, Iowa, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, In c. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), announces the first patient was dosed at the University of Wisconsin in the Company's Phase 1/2a dose escalation trial...
Source: https://incomestatements.info
Category: Stock Reports